Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma By Ogkologos - May 14, 2026 282 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the RMC-6236-001 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Smoking among young adults increased by 25% during first lockdown August 25, 2021 EMA Recommends Granting a Conditional Marketing Authorisation for Alpelisib June 12, 2026 37-Year-Old Mom Breaks American Marathon Record January 21, 2022 Omission of Completion Axillary Lymph Node Dissection Noninferior to More Extensive... April 8, 2024 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Tepotinib Ivosidenib with Chemotherapy New Option for Some People with AML Dad Creates Inclusive Children’s Book For Daughter With Disability And Others... EMA Recommends Extension of Therapeutic Indications for Acalabrutinib
